Repare Therapeutics Management
Management Kriterienprüfungen 2/4
Repare Therapeutics CEO ist Lloyd Segal , ernannt in Sep 2016, hat eine Amtszeit von 8.17 Jahren. Die jährliche Gesamtvergütung beträgt $4.99M , bestehend aus 12.3% Gehalt und 87.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.28% der Aktien des Unternehmens, im Wert von $421.96K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.5 Jahre bzw. 4.7 Jahre.
Wichtige Informationen
Lloyd Segal
Geschäftsführender
US$5.0m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 12.3% |
| Amtszeit als Geschäftsführer | 8.2yrs |
| Eigentum des Geschäftsführers | 0.3% |
| Durchschnittliche Amtszeit des Managements | 5.5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.7yrs |
Jüngste Management Updates
Recent updates
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise
Oct 05
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Aug 30Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$5m | US$615k | -US$94m |
| Sep 30 2023 | n/a | n/a | -US$97m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$4m | US$592k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$132m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$4m | US$572k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$94m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$5m | US$505k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$430k | -US$27m |
Vergütung im Vergleich zum Markt: LloydDie Gesamtvergütung ($USD4.99M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.48M).
Entschädigung vs. Einkommen: LloydDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Lloyd Segal (60 yo)
8.2yrs
Amtszeit
US$4,991,804
Vergütung
Mr. Lloyd Mitchell Segal serves as Director at HotKnot Therapeutics, Inc. Mr. Segal has been the Chief Executive Officer, President and Director of Repare Therapeutics Inc. since September 2016. Mr. Segal...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 8.2yrs | US$4.99m | 0.28% $ 422.0k | |
| Executive VP & CFO | 5.1yrs | US$1.93m | 0.034% $ 51.6k | |
| Executive VP & Chief Medical Officer | 5.5yrs | US$2.09m | 0.47% $ 715.2k | |
| Co-Founder | no data | keine Daten | keine Daten | |
| Co-Founder | no data | keine Daten | keine Daten | |
| Co-Founder | no data | keine Daten | keine Daten | |
| Executive VP & Chief Scientific Officer | 5.5yrs | US$1.83m | 0.098% $ 148.7k | |
| Executive Vice President of Human Resource | 1.5yrs | keine Daten | 0.0037% $ 5.6k | |
| Executive Vice President of Discovery | 8.4yrs | keine Daten | 0.055% $ 83.8k | |
| Executive VP | 2.8yrs | keine Daten | 0.0092% $ 14.0k |
5.5yrs
Durchschnittliche Betriebszugehörigkeit
53yo
Durchschnittliches Alter
Erfahrenes Management: RPTXDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.5 ).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 8.2yrs | US$4.99m | 0.28% $ 422.0k | |
| Independent Director | 4.4yrs | US$274.74k | 0.0094% $ 14.3k | |
| Independent Director | 5.2yrs | US$265.41k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$664.86k | 0% $ 0 | |
| Independent Director | less than a year | keine Daten | keine Daten | |
| Independent Director | 5yrs | US$265.31k | 0% $ 0 | |
| Independent Chairman | 3.2yrs | US$291.49k | 0.018% $ 26.9k | |
| Independent Director | 5.7yrs | US$272.99k | 0.019% $ 28.6k |
4.7yrs
Durchschnittliche Betriebszugehörigkeit
58yo
Durchschnittliches Alter
Erfahrener Vorstand: RPTXDie Vorstandsmitglieder gelten als erfahren (4.7 Jahre durchschnittliche Amtszeit).